Osaka, Japan

Hiroko Ishitani


Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 9(Granted Patents)


Location History:

  • Osaka, JP (2000)
  • Ibaraki, JP (2000)

Company Filing History:


Years Active: 2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hiroko Ishitani: Innovator in Percutaneous Absorption Preparations

Introduction

Hiroko Ishitani is a notable inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceutical technology, particularly in the development of percutaneous absorption preparations. With a total of 2 patents, her work has garnered attention for its innovative approach to drug delivery.

Latest Patents

One of her latest patents focuses on a percutaneous absorption preparation that minimizes coloration phenomena while ensuring excellent stability of the drug content. This preparation consists of a support and a pressure-sensitive adhesive layer formed on at least one side of the support. The adhesive layer contains a percutaneous absorptive drug along with at least one of 2-mercaptobenzimidazole and propyl gallate. Importantly, the percutaneous absorptive drug is not 6-amino-5-chloro-1-isopropyl-2-(4-methyl-1-piperazinyl)benzimidazole or its pharmacologically acceptable salt.

Career Highlights

Throughout her career, Hiroko Ishitani has worked with prominent companies such as Nitto Denko Corporation and Kanebo, Limited. Her experience in these organizations has allowed her to refine her skills and contribute to advancements in her field.

Collaborations

Hiroko has collaborated with notable colleagues, including Takateru Muraoka and Hitoshi Akemi. These partnerships have played a crucial role in her innovative projects and patent developments.

Conclusion

Hiroko Ishitani stands out as a pioneering inventor in the realm of percutaneous absorption preparations. Her contributions continue to influence the pharmaceutical industry, showcasing her dedication to innovation and excellence.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…